Related Experiment Video
Updated: Aug 11, 2026
11:05
Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
Published on: September 19, 2014
Radioimmunoguided breast surgery using radiolabeled antibody NR-LU-10 FAB: a pilot study
W E Burak1, L DePalatis, J L Mosic
1Department of Surgery, The Ohio State University Comprehensive Cancer Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, USA. burak.1@osu.edu
Tumori
|August 16, 2001
Summary
Radioimmunoguided surgery using radiolabeled NR-LU-10 Fab showed promise for intraoperative breast cancer detection, localizing tumors in 70% of patients. However, non-malignant tissue binding limited its effectiveness for margin evaluation.
Area of Science:
- Oncology
- Surgical Oncology
- Nuclear Medicine
Background:
- Breast cancer detection and surgical margin assessment remain critical challenges.
- Intraoperative techniques are sought to improve surgical accuracy and patient outcomes.
Purpose of the Study:
- To evaluate radioimmunoguided surgery with radiolabeled NR-LU-10 Fab for intraoperative breast cancer detection.
- To assess the feasibility and efficacy of this technique in identifying primary tumors and occult lesions.
Main Methods:
- Ten breast cancer patients received intravenous 125I-labeled NR-LU-10 Fab (5 mg, 74 MBq).
- Tumor excision was performed 2, 4, or 7 days post-injection.
- A gamma detector probe was used intraoperatively to assess radioactive uptake in the tumor.
Main Results:
- Tumor localization was achieved in 7 of 10 patients (70%) using intraoperative probing.
- Elevated gamma probe counts were observed in all excised tumors.
- In 3 patients, high counts in surrounding non-malignant tissue hindered in vivo tumor detection.
- One patient with bilateral disease had separate occult tumor foci identified in each breast.
Conclusions:
- Radiolabeled NR-LU-10 Fab demonstrates favorable pharmacokinetics and tumor-binding properties for targeted delivery.
- Binding to non-malignant tissues restricts its current utility in intraoperative margin assessment for breast cancer.
- Further investigation into its application for other malignancies is warranted.
